Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice

Molecular and Cellular Endocrinology

Volumn 325, Issue 1-2, 2010, Pages 101-109

  Tyagi, Abdul M ^a   Gautam, Abnish K ^a   Kumar, Amit ^a   Srivastava, Kamini ^a   Bhargavan, Biju ^a   Trivedi, Ritu ^a   Saravanan, S ^a   Yadav, Dinesk K ^a   Singh, Nidhi ^a   Pollet, Caroline ^b   Brazier, Michel ^b   Mentaverri, Romuald ^b   Maurya, Rakesh ^a   Chattopadhyay, Naibedya ^a   Goel, Atul ^a   Singh, Divya ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b INSERM   (France)

Author keywords

Anti resorptive; Bone microarchitecture; Estrogen receptor; Osteogenic; Selective estrogen receptor modulator

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; MEDICARPIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE CELL; BONE MARROW CELL; CALVARIA; CELL ISOLATION; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; EX VIVO STUDY; FEMALE; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LONG BONE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OVARIECTOMY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELLS, CULTURED; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; ESTROGENS; FEMALE; MICE; OSTEOCLASTS; OVARIECTOMY; PTEROCARPANS; RABBITS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954383266     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.05.016     Document Type: Article

References (53)

1. Abbas S., Zhang Y.H., Clohisy J.C., Abu-Amer Y. Tumor necrosis factor-alpha inhibits pre-osteoblast differentiation through its type-1 receptor. Cytokine 2003, 22:33-41.
2. Ariyoshi W., Takahashi T., Kanno T., Ichimiya H., Shinmyouzu K., et al. Heparin inhibits osteoclastic differentiation and function. J. Cell. Biochem. 2008, 103:1707-1717.
3. Aubin J.E., Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos. Int. 2000, 11:905-913.
4. Baek K.H., Oh K.W., Lee W.Y., Tae H.J., Rhee E.J., et al. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism. Bone 2006, 39:1352-1360.
5. Bandyopadhyay S., Lion J.M., Mentaverri R., Ricupero D.A., Kamel S., et al. Attenuation of osteoclastogenesis and osteoclast function by apigenin. Biochem. Pharmacol. 2006, 72:184-197.
6. Beck U., Rohr A., Jungbauer Phytoestrogens derived from red clover: An alternative to estrogen replacement therapy?. Journal of steroid biochemistry and Molecular Biology 2005, 94(5):499-518.
7. Bhargavan B., Gautam A.K., Singh D., Kumar A., Chaurasia S., et al. Methoxylated isoflavones, cajanin and isoformononetin, have non-estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling. J. Cell. Biochem. 2009, 108:388-399.
8. Bhargavan B., Gautam A.K., Singh D., Kumar A., Chaurasia S., et al. Methoxylated isoflavones, cajanin and isoformononetin, have non-estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling. J. Cell. Biochem. 2009.
9. Boyce B.F., Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res. Ther. 2007, 9(Suppl. 1):S1.
10. Caetano-Lopes J., Canhao H., Fonseca J.E. Osteoblasts and bone formation. Acta Reumatol. Port. 2007, 32:103-110.
11. Charatcharoenwitthaya N., Khosla S., Atkinson E.J., McCready L.K., Riggs B.L. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J. Bone Miner. Res. 2007, 22:724-729.
12. Cocker W., McMurry T.B.H., Staniland P.A. A synthesis of demethylhomopterocarpin. J. Chem. Soc. 1965, 1034-1037.
13. Fujioka M., Sudo Y., Okumura M., Wu J., Uehara M., et al. Differential effects of isoflavones on bone formation in growing male and female mice. Metabolism 2007, 56:1142-1148.
14. Gao Y.H., Yamaguchi M. Suppressive effect of genistein on rat bone osteoclasts: involvement of protein kinase inhibition and protein tyrosine phosphatase activation. Int. J. Mol. Med. 2000, 5:261-267.
15. Gilbert L., He X., Farmer P., Boden S., Kozlowski M., et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000, 141:3956-3964.
16. Giner M., Rios M.A., Montoya M.A., Vazquez M.A., Naji L., Perez-Cano R. RANKL/OPG in primary cultures of osteoblasts from post-menopausal women. Differences between osteoporotic hip fractures and osteoarthritis. J. Steroid Biochem. Mol. Biol. 2009, 113:46-51.
17. Goda Y., Kiuchi F., Shibuya M., Sankawa U. Inhibitor of prostaglandin biosynthesis from Dalbergia odorifera. Chem. Pharm. Bull. 1992, 40:2452-2457.
18. Grassi F., Tell G., Robbie-Ryan M., Gao Y., Terauchi M., et al. Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:15087-15092.
19. Greiner S., Kadow-Romacker A., Schmidmaier G., Wildemann B. Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(d, l-lactide) implant coating. J. Biomed. Mater. Res. A 2009, 91:288-295.
20. Han K.O., Choi J.T., Choi H.A., Moon I.G., Yim C.H., et al. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. Clin. Endocrinol. (Oxf.) 2005, 62:349-353.
21. Hildebrand T., Ruegsegger P. Quantification of bone microarchitecture with the structure model index. Comput. Methods Biomech. Biomed. Eng. 1997, 1:15-23.
22. Hou P., Sato T., Hofstetter W., Foged N.T. Identification and characterization of the insulin-like growth factor I receptor in mature rabbit osteoclasts. J. Bone Miner. Res. 1997, 12:534-540.
23. Hurtel-Lemaire A.S., Mentaverri R., Caudrillier A., Cournarie F., Wattel A., et al. The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J. Biol. Chem. 2009, 284:575-584.
24. Ingham J.L., Harborne J.B. Phytoalexin induction as a new dynamic approach to the study of systematic relationships among higher plants. Nature 1976, 260:241-243.
25. Ishida N., Hayashi K., Hoshijima M., Ogawa T., Koga S., et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 2002, 277:41147-41156.
26. Kameda T., Ishikawa H., Tsutsui T. Detection and characterization of apoptosis in osteoclasts in vitro. Biochem. Biophys. Res. Commun. 1995, 207:753-760.
27. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 2008, 29:155-192.
28. Kim S.H., Shin T.Y. Amomum xanthiodes inhibits mast cell-mediated allergic reactions through the inhibition of histamine release and inflammatory cytokine production. Exp. Biol. Med. (Maywood) 2005, 230:681-687.
29. Kitazawa R., Kimble R.B., Vannice J.L., Kung V.T., Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 1994, 94:2397-2406.
30. Kobayashi Y., Udagawa N., Takahashi N. Action of RANKL and OPG for osteoclastogenesis. Crit. Rev. Eukaryot. Gene Expr. 2009, 19:61-72.
31. Lam J., Nelson C.A., Ross F.P., Teitelbaum S.L., Fremont D.H. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J. Clin. Invest. 2001, 108:971-979.
32. Maggiolini M., Recchia A.G., Bonofiglio D., Catalano S., Vivacqua A., et al. The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor alpha in human breast cancer cells. J. Mol. Endocrinol. 2005, 35:269-281.
33. Marini H., Minutoli L., Polito F., Bitto A., Altavilla D., et al. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after, 2-year genistein administration. J. Bone Miner. Res. 2008, 23:715-720.
34. Mentaverri R., Kamel S., Brazier M. Involvement of capacitive calcium entry and calcium store refilling in osteoclastic survival and bone resorption process. Cell Calcium 2003, 34:169-175.
35. Mentaverri R., Yano S., Chattopadhyay N., Petit L., Kifor O., et al. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J. 2006, 20:2562-2564.
36. Mitani M., Miura Y., Saura R., Kitagawa A., Fukuyama T., et al. Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts. Int. J. Mol. Med. 2005, 15:827-832.
37. Nabaei-Bidhendi G., Bannerjee N.R. Convenient synthesis of, 7-demethylhomoptrerocarpin and, 7-demethylpterocarpin. Indian J. Chem. 1990, 29B:366-368.
38. Nanes M.S. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 2003, 321:1-15.
39. Pacifici R. T cells and post menopausal osteoporosis in murine models. Arthritis Res. Ther. 2007, 9:102.
40. Pandey R., Gautam A.K., Bhargavan B., Trivedi R., Swarnkar G., et al. Total extract and standardized fraction from the Stem-Bark of Butea monosperma have osteoprotective action: evidence for the non-estrogenic osteogenic effect of the standardized fraction. Menopause 2010, 17:602-610.
41. Pang J.L., Ricupero D.A., Huang S., Fatma N., Singh D.P., et al. Differential activity of kaempferol and quercetin in attenuating tumor necrosis factor receptor family signaling in bone cells. Biochem. Pharmacol. 2006, 71:818-826.
42. Pfeilschifter J., Koditz R., Pfohl M., Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 2002, 23:90-119.
43. Quaedackers M.E., Van Den Brink C.E., Wissink S., Schreurs R.H., Gustafsson J.A., et al. 4-Hydroxytamoxifen trans-represses nuclear factor-kappa B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)alpha, and not through ER beta. Endocrinology 2001, 142:1156-1166.
44. Rassi C.M., Lieberherr M., Chaumaz G., Pointillart A., Cournot G. Down-regulation of osteoclast differentiation by daidzein via caspase, 3. J. Bone Miner. Res. 2002, 17:630-638.
45. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13960-13965.
46. Sharan K., Siddiqui J.A., Swarnkar G., Maurya R., Charatcharoenwitthaya N. Role of phytochemicals in the prevention of menopausal bone loss: evidence from in vitro and in vivo, human interventional and pharma-cokinetic studies. Curr. Med. Chem. 2009, 16:1138-1157.
47. Sharan K., Siddiqui J.A., Swarnkar G., Tyagi A.M., Kumar A., et al. Extract and fraction from Ulmus wallichiana planchon promote peak bone mass achievement and have non-estrogenic bone protective effect. Menopause 2010, 17:393-402.
48. Srivastava S., Weitzmann M.N., Cenci S., Ross F.P., Adler S., Pacifici R. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J. Clin. Invest. 1999, 104:503-513.
49. Trivedi R., Kumar S., Kumar A., Siddiqui J.A., Swarnkar G., et al. Kaempferol has osteogenic effect in ovariectomized adult Sprague-Dawley rats. Mol. Cell. Endocrinol. 2008, 289:85-93.
50. Trivedi R., Kumar A., Gupta V., Kumar S., Nagar G.K., et al. Effects of Egb, 761 on bone mineral density, bone microstructure, and osteoblast function: possible roles of quercetin and kaempferol. Mol. Cell. Endocrinol. 2009, 302:86-91.
51. Vargas S.J., Naprta A., Glaccum M., Lee S.K., Kalinowski J., Lorenzo J.A. Interleukin-6 expression and histomorphometry of bones from mice deficient in receptors for interleukin-1 or tumor necrosis factor. J. Bone Miner. Res. 1996, 11:1736-1744.
52. Yamagishi T., Otsuka E., Hagiwara H. Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. Endocrinology 2001, 142:3632-3637.
53. Zhou F.H., Foster B.K., Zhou X.F., Cowin A.J., Xian C.J. TNF-alpha mediates p38 MAP kinase activation and negatively regulates bone formation at the injured growth plate in rats. J. Bone Miner. Res. 2006, 21:1075-1088.